Literature DB >> 14582732

Antibiotic susceptibilities of recent isolates of Mycoplasma bovis in Belgium.

A Thomas1, C Nicolas, I Dizier, J Mainil, A Linden.   

Abstract

The susceptibilities of 40 recent Belgian field isolates of Mycoplasma bovis to 10 antimicrobial agents were assessed. Tiamulin was the most active antimicrobial agent against M bovis, with an initial inhibitory concentration (IIC50) of 0.06 microg/ml, but it is not licensed for the treatment of cattle. All three fluoroquinolones tested (danofloxacin, enrofloxacin and marbofloxacin) were effective against strains of M bovis, and had a minimum mycoplasmacidal concentration (MMC50) less than or equal to 1 microg/ml. Gentamicin was poorly effective, having an IIC50 of 8 microg/ml. Many strains of M bovis were resistant to tylosin, spectinomycin, lincomycin, tetracycline and oxytetracycline.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582732     DOI: 10.1136/vr.153.14.428

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  12 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  In vitro susceptibilities of Mycoplasma hyopneumoniae field isolates.

Authors:  J Vicca; T Stakenborg; D Maes; P Butaye; J Peeters; A de Kruif; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

Authors:  E Amram; I Mikula; C Schnee; R D Ayling; R A J Nicholas; R S Rosales; S Harrus; I Lysnyansky
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

4.  Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal.

Authors:  Dima Khalil; Claire A M Becker; Florence Tardy
Journal:  Appl Environ Microbiol       Date:  2015-12-04       Impact factor: 4.792

5.  Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.

Authors:  Anne V Gautier-Bouchardon; Séverine Ferré; Dominique Le Grand; Agnès Paoli; Emilie Gay; François Poumarat
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

6.  Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Lilla Fekete; Veronika Hrivnák; Tibor Magyar; Szilárd Jánosi; Nóra Schweitzer; Ibolya Turcsányi; László Makrai; Károly Erdélyi; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2014-10-25       Impact factor: 2.741

7.  Integrated pharmacokinetic-Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets.

Authors:  Qing Lin Zeng; Xian Mei; Jia Su; Xiao Hong Li; Wen Guang Xiong; Yan Lu; Zhen Ling Zeng
Journal:  BMC Vet Res       Date:  2017-06-15       Impact factor: 2.741

Review 8.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.

Authors:  Inna Lysnyansky; Roger D Ayling
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

9.  Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.

Authors:  Ying Qu; Zhenzhen Qiu; Changfu Cao; Yan Lu; Meizhen Sun; Chaoping Liang; Zhenling Zeng
Journal:  BMC Vet Res       Date:  2015-12-02       Impact factor: 2.741

10.  Clinical-pathological findings of otitis media and media-interna in calves and (clinical) evaluation of a standardized therapeutic protocol.

Authors:  I Bertone; C Bellino; G L Alborali; A Cagnasso; G Cagnotti; E Dappiano; M Lizzi; M Miciletta; A Ramacciotti; P Gianella; A D'Angelo
Journal:  BMC Vet Res       Date:  2015-12-03       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.